News | Neuro Imaging | July 05, 2019

Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden

Clinical data shows Delta T1 maps from Imaging Biometrics on par with central reader analysis but offer substantial time and cost savings

Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden

July 5, 2019 — Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American Journal of Neuroradiology1 confirming the value of IB’s dT1 maps in streamlining routine radiology workflows and multi-center clinical trials.

The study confirms the value of IB’s dT1 maps in streamlining routine radiology workflows and multi-center clinical trials.

Objective, accurate and reproducible methods to measure brain tumor volumes are important in the assessment of treatment response. Contrast-enhanced magnetic resonance imaging (MRI) is the most common approach to monitor treatment, but it is highly variable and confounded by numerous factors including differences in vendor platforms, field strengths and general MRI system instabilities. It is well-acknowledged that these factors contribute to the large disagreement of up to 50-60 percent between neuroradiologists when assessing tumor burden and evaluating treatment response.

Quantitative dT1 maps offer an elegant and automated solution that overcome these challenges and, therefore, have the potential to cause a disruptive shift in how brain tumor burden is assessed. dT1 maps compare calibrated pre- (T1) and post-contrast (T1+C) anatomic images. The calibration process, exclusive to IB, translates the relative and variable MR intensity values to a fixed and consistent scale. This built-in step is independent of scanner platform, field strength and time point, and has been shown superior over manual tissue normalization algorithms.

The secondary analysis of multicenter clinical trial data was performed by lead author Kathleen Schmainda, Ph.D., from the Medical College of Wisconsin, and colleagues. In total, 123 patients from 23 institutions enrolled in the study. The study compared IB’s dT1 maps to two primary readers and one adjudicator to manually delineate enhancing lesions. The results proved the dT1 method to be comparable to expert reads for determining early tumor progression and proved superior for further distinguishing treatment responders from non-responders at the week 8 time point. Another key outcome of the study was that only the dT1 method could predict differences in outcomes at the week 8 time point.\

For more information: www.imagingbiometrics.com

 

Reference

1. Schmainda K.M., Prah M.A., Zhang Z., et al. Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial. American Journal of Neuroradiology, June 27, 2019. doi: 10.3174/ajnr.A6110

Related Content

Densitas Wins Major Procurement of Breast Density Software for DIMASOS Breast Screening Trial
News | Breast Density | September 20, 2019
Densitas Inc. announced it has won a procurement of its densitas densityai software for deployment in up to 24 breast...
Screening Mammography Could Benefit Men at High Risk of Breast Cancer
News | Mammography | September 18, 2019
Selective mammography screening can provide potentially lifesaving early detection of breast cancer in men who are at...
Radiation After Immunotherapy Improves Progression-free Survival for Some Metastatic Lung Cancer Patients
News | Lung Cancer | September 18, 2019
Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates...
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Radiation Therapy | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of...
Long-term Hormone Therapy Increases Mortality Risk for Low-PSA Men After Prostate Surgery
News | Prostate Cancer | September 16, 2019
Secondary analysis of a recent clinical trial that changed the standard of care for men with recurring prostate cancer...
Imaging Biometrics and Medical College of Wisconsin Awarded NIH Grant
News | Neuro Imaging | September 09, 2019
Imaging Biometrics LLC (IB), in collaboration with the Medical College of Wisconsin (MCW), has received a $2.75 million...
ASNC Announces Multisocietal Cardiac Amyloidosis Imaging Consensus
News | Cardiac Imaging | September 09, 2019
September 9, 2019 — The American Society of Nuclear Cardiology (ASNC) published a new expert consensus document along
AJR Publishes Gender Affirmation Surgery Primer for Radiologists. transgender radiology images,

Scout image from contrast-enhanced CT shows erectile implant; stainless steel and silicone anchors (arrow) transfixed to pubic bone are asymmetric.

News | Orthopedic Imaging | September 05, 2019
September 5, 2019 — An ahead-of-print article published in the December issue of the American Journal of Roentgen
Neurological Brain Markers Might Detect Risk for Psychotic Disorders

Researchers at the University of Missouri used MRI scans similar to this photo to find neurological markers in the human brain. These markers can be used to detect people at risk for developing psychotic disorders and to understand when this risk has been successfully treated. Image courtesy of Marquette University/John Kerns.

News | Neuro Imaging | September 04, 2019
Help may be on the way for people who might lose contact with reality through a psychotic disorder, such as...
Medical Imaging Rates Continue to Rise Despite Push to Reduce Their Use
News | Radiology Imaging | September 03, 2019
Despite a broad campaign among physician groups to reduce the amount of medical imaging, use rates of various scans...